A Phase 3 interventional study of Olanzapine and Placebo in Depression, Bipolar, sponsored by Eli Lilly and Company. Completed at 16 sites in 3 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2011-05-26.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing olanzapine in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Olanzapine · Bipolar Disorder.
Among the 28 studies testing olanzapine in Bipolar Disorder, this one has the largest enrollment, is one of 4 that started in 2007, is one of 7 in phase 3, and was the 21st registered.
1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →None of the 28 studies testing olanzapine in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →
Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 514 is above the median of 64 across 1,280 interventional studies indexed under Bipolar Disorder.
Median enrollment 120 across the 28 interventional studies. Of the 27 that completed or were terminated, 8 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 28 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
20 studies in Bipolar Disorder by Eli Lilly and Company: 1 open now, 1 under way, none of them phase 3. Of 19 finished, 5 (26%) have results posted.
Among the 20 studies in Bipolar Disorder by Eli Lilly and Company, this one has the largest enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2007, is one of 5 in phase 3, and was the 14th registered.
Eli Lilly and Company’s Bipolar Disorder studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing olanzapine in Bipolar Disorder, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 20 in Bipolar Disorder:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess whether olanzapine is superior to placebo in patients with bipolar depression.
Duration:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During double-blind treatment, participants receive olanzapine at a dose of 5 milligram (mg) which is increased to 10 mg per day no later than 3-7 days after randomization (Baseline). Subsequent dose increases above 10 mg (up to a maximum of 20 mg per day) are permitted in 5 mg per day increments, based upon tolerability and symptoms. Dosing may be decreased by any number of decrements, however dosing below 5 mg requires study discontinuation.
Drug: Olanzapine
Matching placebo administered once daily, by mouth during double-blind treatment.
Drug: Placebo
During open-label treatment, participants randomized to placebo in double-blind period will receive olanzapine 5 mg starting at Week 6. Participants randomized to olanzapine must be at a 5 mg olanzapine dose at Week 7. Those on higher doses will be reduced between Week 6 and Week 7 (10 mg reduced to 5 mg; 15 mg reduced to 10 mg and then to 5 mg at Week 7; 20 mg reduced to 15 mg and then 10 mg to dosing at 5 mg at Week 7). Dose increases beyond Week 7 are permitted and at the investigator's discretion.
Drug: Olanzapine
5-20 mg, oral, once daily, for 24 weeks (participants randomized to olanzapine in double-blind treatment period) or 18 weeks (participants randomized to placebo in double-blind treatment period).
Also known as: LY170053, Zyprexa
placebo tablets, oral, once daily at bedtime, 6 weeks
Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score (Acute Phase)
The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
Time frame: Baseline, Endpoint (Week 6)
Percentage of Participants With Symptomatic Response at Endpoint (Acute Phase)
Response is defined as a reduction (from baseline to endpoint) of 50% or more in the MADRS total score. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
Time frame: Endpoint (Week 6)
Percentage of Participants With Symptomatic Remission At Any Time (Acute Phase)
Percentage of participants with symptomatic remission at any time as defined as a score of less than or equal to 12 in the MADRS total score. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
Time frame: Baseline through Endpoint (Week 6)
Change From Baseline to Endpoint in Clinical Global Improvement- Bipolar (CGI-BP) Severity of Illness Scores-Mania, Depression, Overall Bipolar Illness Scores (Acute Phase)
CGI-BP is a measure of illness severity especially adapted for bipolar illness. It allows rating of mania, depression, and overall illness. The score ranges from 1 (normal, not ill) to 7 (very seriously ill).
Time frame: Baseline, Endpoint (Week 6)
Percentage of Participants With Recovery (Acute Phase)
Percentage of participants with recovery defined as a value of less than or equal to 12 in the MADRS total score for at least 4 weeks of post-baseline treatment. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
Time frame: Baseline through Endpoint (Week 6 )
Change From Baseline to Endpoint in Young Mania Rating Scale (YMRS) Total Score (Acute Phase)
The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.
Time frame: Baseline, Endpoint (Week 6)
Change From Baseline to Endpoint in Hamilton Depression Rating Scale-17 (HAMD-17) Total Score (Acute Phase)
The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).
Time frame: Baseline, Endpoint (Week 6)
Percentage of Participants With Major Depressive Episode at Endpoint on Mini International Neuropsychiatric Interview (MINI), Depressive Episode Module (Acute Phase)
In the MINI Major Depressive Episode module, participants are asked a series of Yes/No questions to determine whether or not they are experiencing a major depressive episode or a major depressive episode with melancholic features.
Time frame: Endpoint (Week 6)
Percentage of Participants With Current Hypomanic Episode at Endpoint on MINI Manic Episode Module (Acute Phase)
In the MINI Manic Episode module, participants are asked a series of Yes/No questions to determine whether or not they are currently experiencing hypomanic or manic episodes.
Time frame: Endpoint (Week 6)
Percentage of Participants With Psychotic Disorders and Mood Disorders With Psychotic Features at Endpoint on MINI Psychotic Disorders Module (Acute Phase)
In the MINI Psychotic Features Episode module, participants are asked a series of Yes/No questions to determine whether or not they are currently experiencing mood disorder with psychotic features or current psychotic disorders.
Time frame: Endpoint (Week 6)
Percentage of Participants With Alcohol Dependence and Abuse at Endpoint on MINI Alcohol Dependence/Abuse Module (Acute Phase)
In the MINI Alcohol Abuse and Dependence Module, participants are asked a series of Yes/No questions to determine whether or not they are currently experiencing symptoms indicating current alcohol dependence or abuse.
Time frame: Endpoint (Week 6)
Percentage of Participants With Non-Alcohol Psychoactive Substance Use Disorder at Endpoint on MINI Substance Dependence/Abuse Module (Acute Phase)
In the MINI Substance Dependence and Abuse Module, participants are asked a series of Yes/No questions to determine whether or not they are currently experiencing symptoms indicating current non-alcohol substance use dependence or abuse.
Time frame: Endpoint (Week 6)
Percentage of Participants With Emergence of Mania During the Study (Acute Phase)
Emergence of mania is defined as first occurrence of score of \>=15 in the YMRS total score in the post-baseline period of Acute Phase. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.
Time frame: Baseline through Endpoint (Week 6)
Percentage of Participants With Extra-Pyramidal Symptoms (EPS) At Endpoint As Measured by Drug-Induced Extra-Pyramidal Symptoms Scale (DIEPSS) (Acute Phase)
EPS symptoms measured by DIEPSS are grouped into 4 categories: parkinsonism, akathisia, dystonia, and dyskinesia. Severity is assessed at 5 levels, from level 0 (none, normal) to level 4 (severe). For Parkinsonism, normal baseline is defined as a score not \>=3 on 1 item nor \>=2 on 2 items; abnormal endpoint is defined as a score \>=3 on 1 item or \>=2 on 2 items, or an increase of 3 on Parkinsonism total. Baseline akathisia, dystonia and dyskinesia is defined as a score \<2; abnormal endpoint is a score \>=2 or an increase \>= 2 from that baseline score.
Time frame: Endpoint (Week 6)
Change From Baseline to Endpoint in Blood Pressure (Acute Phase)
Time frame: Baseline, Endpoint (Week 6)
Change From Baseline to Endpoint in Weight (Acute Phase)
Time frame: Baseline, Endpoint (Week 6)
Change From Baseline to Endpoint in Glucose and Lipids (Cholesterol, Triglycerides, HDL Cholesterol, LDL Cholesterol)
Time frame: Baseline, Endpoint (Week 6)
Change From Baseline to Endpoint in Albumin (Acute Phase)
Time frame: Baseline, Endpoint (Week 6)
Change From Baseline to Endpoint in Alanine Amino Transferase/Serum Glutamate Pyruvate Transaminase (ALT/SGPT), Aspartate Aminotransferase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT), Gamma Glutamyl Transferase (GGT)
Time frame: Baseline, Endpoint (Week 6)
Change From Baseline to Endpoint in Direct Bilirubin, Total Bilirubin, Uric Acid (Acute Phase)
Time frame: Baseline, Endpoint (Week 6)
Change From Baseline to Endpoint in Erythrocyte Count (Acute Phase)
Time frame: Baseline, Endpoint (Week 6)
Change From Baseline to Endpoint in Hematocrit (Acute Phase)
Time frame: Baseline, Endpoint (Week 6)
Change From Baseline to Endpoint in Hemoglobin A1c (Acute Phase)
Time frame: Baseline, Endpoint (Week 6)
Change From Baseline to Endpoint in Hemoglobin (Acute Phase)
Time frame: Baseline, Endpoint (Week 6)
Change From Baseline to Endpoint in Prolactin (Acute Phase)
Time frame: Baseline, Endpoint (Week 6)
Change From Baseline to Endpoint in Urinalysis (UA)- Specific Gravity (Acute Phase)
Time frame: Baseline, Endpoint (Week 6)
Change in Electrocardiogram (ECG) From Baseline to Endpoint (Acute Phase)
Time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole, fixed correction factor (QTcF interval); Bazett-Corrected QT Interval (QTcB interval).
Time frame: Baseline, Endpoint (Week 6)
Change From Baseline to Endpoint in Heart Rate (Acute Phase)
Time frame: Baseline, Endpoint (Week 6)
Change From Baseline to Endpoint in MINI Suicidality Total Scores (Acute Phase)
The MINI module C (MINI-C) is a rating scale for severity of suicidal thoughts and behaviors. The MINI-C is composed of 12 Yes/No questions with variable scores assigned to each question. The scale ranges from 0 to 52 with higher scores indicating a greater presence of suicidal thoughts and/or behaviors.
Time frame: Baseline, Endpoint (Week 6)
Number of Participants With Adverse Events (Acute Phase)
Please refer to the Adverse Event overview for details regarding adverse events and serious adverse events.
Time frame: Baseline through Week 6 (Acute Phase)
Percentage of Participants With Symptomatic Response in Montgomery-Asberg Depression Rating (MADRS) Depression Rating (Open-Label Phase)
The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Response is defined as a reduction (from baseline to endpoint) of 50% or more in the MADRS total score.
Time frame: Baseline (End of Acute Phase/Week 6) through Endpoint (Week 24)
Percentage of Participants With Symptomatic Remission in the MADRS Total Score (Open-Label Phase)
Percentage of participants with symptomatic remission at any time as defined as a score of less than or equal to 12 in the MADRS total score. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
Time frame: Baseline (End of Acute Phase/Week 6) through Endpoint (Week 24)
Percentage of Participants With Recovery (Open-Label Phase)
Percentage of participants with recovery defined as a value of less than or equal to 12 in the MADRS total score for at least 4 weeks of post-baseline treatment. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
Time frame: Baseline (End of Acute Phase/Week 6) through Endpoint (Week 24)
Change From Baseline to Endpoint in Young Mania Rating Scale (YMRS) Total Score (Open-Label Phase)
The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.
Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Percentage of Participants With Emergence of Mania During the Study (Open-Label Phase)
Emergence of mania is defined as first occurrence of score of \>=15 in the YMRS total score in the Open-Label Extension. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.
Time frame: Baseline (End of Acute Phase/Week 6) through Endpoint (Week 24)
Percentage of Participants With Extra-Pyramidal Symptoms (EPS) at Endpoint As Measured by Drug-Induced Extra-Pyramidal Symptoms Scale (DIEPSS) (Open-Label Phase)
EPS symptoms measured by DIEPSS are grouped into 4 categories: parkinsonism, akathisia, dystonia, and dyskinesia. Severity is assessed at 5 levels, from level 0 (none, normal) to level 4 (severe). For Parkinsonism, normal baseline is defined as a score not \>=3 on 1 item nor \>=2 on 2 items; abnormal endpoint is defined as a score \>=3 on 1 item or \>=2 on 2 items, or an increase of 3 on Parkinsonism total. Baseline akathisia, dystonia and dyskinesia is defined as a score \<2; abnormal endpoint is a score \>=2 or an increase \>= 2 from that baseline score.
Time frame: Endpoint (Week 24)
Change From Baseline to Endpoint in Blood Pressure (Open-Label Phase)
Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Change From Baseline to Endpoint in Weight (Open-Label Phase)
Time frame: Baseline (End of Acute Phase/ Week 6), Endpoint (Week 24)
Change From Baseline to Endpoint in Albumin and Total Protein (Open-Label Phase)
Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Change From Baseline to Endpoint in Alkaline Phosphatase, Creatinine Phosphokinase (CPK), GGT (Open-Label Phase)
Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Change From Baseline to Endpoint in Chloride (Open-Label Phase)
Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Change From Baseline to Endpoint in Creatinine (Open-Label Phase)
Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Change From Baseline to Endpoint in Erythrocyte Count (Open-Label Phase)
Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Change From Baseline to Endpoint in Hemoglobin (Open-Label Phase)
Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Change From Baseline to Endpoint in Platelet Count (Open-Label Phase)
Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Change From Baseline to Endpoint in Prolactin (Open-Label Phase)
Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Change From Baseline to Endpoint in Uric Acid (Open-Label Phase)
Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Change From Baseline to Endpoint in Glucose and Lipids (Cholesterol, Triglycerides, HDL Cholesterol, LDL Cholesterol) (Open-Label Phase)
Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Change From Baseline to Endpoint in ECG (Open-Label Phase)
Time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole, fixed correction factor (QTcF interval); Bazett-Corrected QT Interval (QTcB interval).
Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Change From Baseline to Endpoint in Heart Rate (Open-Label Phase)
Time frame: Baseline (End of Acute Phase/Week 6), Endpoint (Week 24)
Percentage of Participants With High Suicidality at Endpoint (Open-Label Phase)
The MINI module C (MINI-C) is a rating scale for severity of suicidal thoughts and behaviors. The MINI-C is composed of 12 Yes/No questions with variable scores assigned to each question. The scale ranges from 0 to 52 with higher scores indicating a greater presence of suicidal thoughts and/or behaviors. Based upon scores, suicidality is defined as Low (1-8), Medium (9-16), and High (\>=17).
Time frame: Endpoint (Week 24)
Number of Participants With Adverse Events (Open-Label Phase)
Please refer to the Adverse Event overview for details regarding adverse events and serious adverse events.
Time frame: Baseline (End of Acute Phase/Week 6) through Endpoint (Week 24)
| Milestone | Olanzapine | Placebo |
|---|---|---|
| Started | 343 | 171 |
| Completed | 267 | 122 |
| Not completed | 76 | 49 |
| Withdrew: Adverse event | 30 | 13 |
| Withdrew: Lack of efficacy | 6 | 13 |
| Withdrew: Lost to follow-up | 3 | 7 |
| Withdrew: Physician decision | 6 | 0 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Withdrawal by subject | 27 | 13 |
| Withdrew: Clinical relapse | 0 | 1 |
| Withdrew: Entry criteria not met | 3 | 0 |
| Milestone | Olanzapine | Placebo |
|---|---|---|
| Started | 267 | 122 |
| Completed | 196 | 96 |
| Not completed | 71 | 26 |
| Withdrew: Adverse event | 22 | 8 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Lack of efficacy | 4 | 0 |
| Withdrew: Lost to follow-up | 10 | 1 |
| Withdrew: Physician decision | 3 | 1 |
| Withdrew: Protocol violation | 4 | 2 |
| Withdrew: Withdrawal by subject | 24 | 12 |
| Withdrew: Clinical relapse | 1 | 1 |
| Withdrew: Sponsor decision | 2 | 0 |
The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
| units on a scale | Olanzapine | Placebo |
|---|---|---|
| Baseline | 29.36 ± 5.71 | 28.69 ± 6.33 |
| Change | -14.26 ± 9.73 | -11.71 ± 11.09 |
Response is defined as a reduction (from baseline to endpoint) of 50% or more in the MADRS total score. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
| percentage of participants | Olanzapine | Placebo |
|---|---|---|
| Percentage of Participants With Symptomatic Response at Endpoint (Acute Phase) | 52.5 | 43.3 |
Percentage of participants with symptomatic remission at any time as defined as a score of less than or equal to 12 in the MADRS total score. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
| percentage of participants | Olanzapine | Placebo |
|---|---|---|
| Percentage of Participants With Symptomatic Remission At Any Time (Acute Phase) | 53.9 | 49.7 |
CGI-BP is a measure of illness severity especially adapted for bipolar illness. It allows rating of mania, depression, and overall illness. The score ranges from 1 (normal, not ill) to 7 (very seriously ill).
| units on a scale | Olanzapine | Placebo |
|---|---|---|
| Baseline-Mania | 1.07 ± 0.29 | 1.11 ± 0.35 |
| Change-Mania | 0.00 ± 0.43 | 0.09 ± 0.59 |
| Baseline-Depression | 4.54 ± 0.73 | 4.53 ± 0.73 |
| Change-Depression | -1.45 ± 1.26 | -1.20 ± 1.36 |
| Baseline- Overall | 4.45 ± 0.79 | 4.44 ± 0.79 |
| Change- Overall | -1.40 ± 1.28 | -1.08 ± 1.27 |
Percentage of participants with recovery defined as a value of less than or equal to 12 in the MADRS total score for at least 4 weeks of post-baseline treatment. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
| percentage of participants | Olanzapine | Placebo |
|---|---|---|
| Percentage of Participants With Recovery (Acute Phase) | 13.7 | 9.4 |
The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.
| units on a scale | Olanzapine | Placebo |
|---|---|---|
| Baseline | 2.14 ± 2.10 | 1.95 ± 2.18 |
| Change | -0.78 ± 2.56 | 0.31 ± 4.21 |
The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).
| units on a scale | Olanzapine | Placebo |
|---|---|---|
| Baseline | 22.62 ± 3.47 | 22.35 ± 3.53 |
| Change | -11.44 ± 7.02 | -9.12 ± 7.99 |
In the MINI Major Depressive Episode module, participants are asked a series of Yes/No questions to determine whether or not they are experiencing a major depressive episode or a major depressive episode with melancholic features.
| percentage of participants | Olanzapine | Placebo |
|---|---|---|
| Major Depressive Episode | 55.5 | 60.4 |
| Major Depressive Episode with Melancholic Features | 77.8 | 74.1 |
In the MINI Manic Episode module, participants are asked a series of Yes/No questions to determine whether or not they are currently experiencing hypomanic or manic episodes.
| percentage of participants | Olanzapine | Placebo |
|---|---|---|
| Percentage of Participants With Current Hypomanic Episode at Endpoint on MINI Manic Episode Module (Acute Phase) | 2.1 | 0.6 |
In the MINI Psychotic Features Episode module, participants are asked a series of Yes/No questions to determine whether or not they are currently experiencing mood disorder with psychotic features or current psychotic disorders.
| percentage of participants | Olanzapine | Placebo |
|---|---|---|
| Mood Disorder with Psychotic Features | 3.6 | 2.4 |
| Psychotic Disorders | 0.0 | 0.6 |
In the MINI Alcohol Abuse and Dependence Module, participants are asked a series of Yes/No questions to determine whether or not they are currently experiencing symptoms indicating current alcohol dependence or abuse.
| percentage of participants | Olanzapine | Placebo |
|---|---|---|
| Dependence | 0.6 | 0.6 |
| Abuse | 0.6 | 0.0 |
In the MINI Substance Dependence and Abuse Module, participants are asked a series of Yes/No questions to determine whether or not they are currently experiencing symptoms indicating current non-alcohol substance use dependence or abuse.
| percentage of participants | Olanzapine | Placebo |
|---|---|---|
| Dependence | 0.0 | 0.0 |
| Abuse | 0.0 | 0.0 |
Emergence of mania is defined as first occurrence of score of \>=15 in the YMRS total score in the post-baseline period of Acute Phase. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.
| percentage of participants | Olanzapine | Placebo |
|---|---|---|
| Percentage of Participants With Emergence of Mania During the Study (Acute Phase) | 0.6 | 2.9 |
EPS symptoms measured by DIEPSS are grouped into 4 categories: parkinsonism, akathisia, dystonia, and dyskinesia. Severity is assessed at 5 levels, from level 0 (none, normal) to level 4 (severe). For Parkinsonism, normal baseline is defined as a score not \>=3 on 1 item nor \>=2 on 2 items; abnormal endpoint is defined as a score \>=3 on 1 item or \>=2 on 2 items, or an increase of 3 on Parkinsonism total. Baseline akathisia, dystonia and dyskinesia is defined as a score \<2; abnormal endpoint is a score \>=2 or an increase \>= 2 from that baseline score.
| percentage of participants | Olanzapine | Placebo |
|---|---|---|
| Akathisia (N=335, 169) | 2.7 | 1.2 |
| Dyskinesia (N=337, 169) | 0.0 | 0.0 |
| Dystonia (N=337, 169) | 0.0 | 0.0 |
| Parkinsonism (N=337, 169) | 0.9 | 0.6 |
| mmHg (millimeters of mercury) | Olanzapine | Placebo |
|---|---|---|
| Baseline- Standing Systolic (N=320, 159) | 112.39 ± 13.25 | 115.65 ± 14.39 |
| Change- Standing Systolic (N=320, 159) | -0.99 ± 10.83 | -0.67 ± 11.18 |
| Baseline- Sitting Systolic (N=340, 169) | 112.35 ± 13.42 | 114.39 ± 13.67 |
| Change- Sitting Systolic (N=340, 169) | -0.36 ± 11.10 | 0.04 ± 12.16 |
| Baseline- Standing Diastolic (N=320, 159) | 74.77 ± 10.20 | 76.87 ± 10.26 |
| Change- Standing Diastolic (N=320, 159) | -0.48 ± 8.71 | -0.14 ± 8.44 |
| Baseline- Sitting Diastolic (N=340, 169) | 73.07 ± 9.93 | 73.92 ± 9.86 |
| Change- Sitting Diastolic (N=340, 169) | -0.11 ± 9.37 | 0.39 ± 9.08 |
| Baseline- Orthostatic Change-Systolic (N=320, 159) | 0.54 ± 6.51 | 1.21 ± 7.67 |
| Change- Orthostatic Change-Systolic (N=320, 159) | -0.65 ± 8.20 | -0.45 ± 11.45 |
| Baseline- Orthostatic Change-Diastolic (N=320, 159 | 1.92 ± 5.93 | 2.96 ± 5.57 |
| Change- Orthostatic Change-Diastolic (N=320, 159) | -0.52 ± 6.79 | -0.47 ± 6.78 |
| kilograms | Olanzapine | Placebo |
|---|---|---|
| Baseline | 66.11 ± 18.11 | 68.30 ± 18.73 |
| Endpoint | 2.45 ± 2.82 | -0.13 ± 2.10 |
| millimole/Liter | Olanzapine | Placebo |
|---|---|---|
| Baseline- Fasting Glucose (N=320, 155) | 5.11 ± 0.58 | 5.12 ± 0.57 |
| Change- Fasting Glucose (N=320, 155) | 0.10 ± 0.61 | 0.02 ± 0.54 |
| Baseline- Cholesterol (N=329, 160) | 4.83 ± 1.01 | 4.81 ± 1.00 |
| Change- Cholesterol (N=329, 160) | 0.24 ± 0.76 | -0.07 ± 0.49 |
| Baseline-Triglycerides (N=329, 160) | 1.39 ± 0.85 | 1.34 ± 0.80 |
| Change- Triglycerides (N=329, 160) | 0.26 ± 0.97 | 0.03 ± 0.71 |
| Baseline- LDL Cholesterol (N=328, 159) | 2.77 ± 0.87 | 2.83 ± 0.84 |
| Change- LDL Cholesterol (N=328, 159) | 0.17 ± 0.66 | -0.09 ± 0.48 |
| Baseline- HDL Cholesterol (N=329, 160) | 1.43 ± 0.41 | 1.36 ± 0.35 |
| Change- HDL Cholesterol (N=329, 160) | -0.03 ± 0.25 | 0.02 ± 0.21 |
| gram/Liter | Olanzapine | Placebo |
|---|---|---|
| Baseline | 43.07 ± 3.85 | 43.47 ± 3.69 |
| Change | -0.81 ± 2.89 | 0.03 ± 3.11 |
| units/Liter | Olanzapine | Placebo |
|---|---|---|
| Baseline (ALT/SGPT) | 21.68 ± 16.53 | 21.18 ± 13.17 |
| Change (ALT/SGPT) | 8.34 ± 26.90 | 0.00 ± 13.63 |
| Baseline (AST/SGOT) | 21.61 ± 8.34 | 20.25 ± 6.70 |
| Change (AST/SGOT) | 4.31 ± 15.66 | 1.26 ± 11.06 |
| Baseline (GGT) | 24.87 ± 36.59 | 23.63 ± 23.17 |
| Change (GGT) | 5.36 ± 22.70 | -1.21 ± 11.67 |
| micromole/Liter | Olanzapine | Placebo |
|---|---|---|
| Baseline- Direct Bilirubin | 2.45 ± 1.23 | 2.40 ± 1.08 |
| Change- Direct Bilirubin | -0.21 ± 1.03 | 0.12 ± 1.02 |
| Baseline- Total Bilirubin | 9.74 ± 5.18 | 9.42 ± 4.58 |
| Change- Total Bilirubin | -0.68 ± 4.57 | 0.47 ± 4.27 |
| Baseline- Uric Acid | 307.19 ± 92.03 | 314.38 ± 86.69 |
| Change- Uric Acid | 19.55 ± 51.10 | -1.86 ± 50.37 |
| trillion cells per liter ( TRIL/L) | Olanzapine | Placebo |
|---|---|---|
| Baseline | 4.65 ± 0.51 | 4.71 ± 0.52 |
| Change | -0.05 ± 0.27 | 0.02 ± 0.27 |
| proportion of blood volume | Olanzapine | Placebo |
|---|---|---|
| Baseline | 0.42 ± 0.04 | 0.43 ± 0.05 |
| Change | -0.01 ± 0.03 | 0.00 ± 0.03 |
| percent of glycosylated hemoglobin | Olanzapine | Placebo |
|---|---|---|
| Baseline | 5.34 ± 0.37 | 5.37 ± 0.37 |
| Change | 0.04 ± 0.26 | -0.03 ± 0.28 |
| millimole/Liter of iron (Fe) | Olanzapine | Placebo |
|---|---|---|
| Baseline | 8.65 ± 0.99 | 8.73 ± 0.97 |
| Change | -0.11 ± 0.50 | 0.05 ± 0.50 |
| microgram/Liter | Olanzapine | Placebo |
|---|---|---|
| Baseline | 15.40 ± 16.89 | 15.86 ± 21.54 |
| Change | 12.07 ± 24.00 | -1.18 ± 26.49 |
| ratio | Olanzapine | Placebo |
|---|---|---|
| Baseline | 1.02 ± 0.01 | 1.02 ± 0.01 |
| Change | -0.00 ± 0.01 | 0.00 ± 0.01 |
Time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole, fixed correction factor (QTcF interval); Bazett-Corrected QT Interval (QTcB interval).
| milliseconds | Olanzapine | Placebo |
|---|---|---|
| Baseline- QTcF | 406.85 ± 19.53 | 408.10 ± 18.72 |
| Change- QTcF | 2.82 ± 14.21 | 0.50 ± 12.27 |
| Baseline- QTcB | 415.79 ± 20.55 | 418.42 ± 19.95 |
| Change- QTcB | 6.58 ± 18.01 | 1.21 ± 16.02 |
| beats per minute (bpm) | Olanzapine | Placebo |
|---|---|---|
| Baseline | 69.63 ± 12.65 | 70.51 ± 11.94 |
| Change | 3.49 ± 11.18 | 0.87 ± 11.51 |
The MINI module C (MINI-C) is a rating scale for severity of suicidal thoughts and behaviors. The MINI-C is composed of 12 Yes/No questions with variable scores assigned to each question. The scale ranges from 0 to 52 with higher scores indicating a greater presence of suicidal thoughts and/or behaviors.
| units on a scale | Olanzapine | Placebo |
|---|---|---|
| Baseline | 2.09 ± 3.44 | 2.40 ± 3.49 |
| Change | -0.42 ± 3.71 | -0.59 ± 3.44 |
Please refer to the Adverse Event overview for details regarding adverse events and serious adverse events.
| participants | Olanzapine | Placebo |
|---|---|---|
| Serious | 6 | 7 |
| Non-Serious | 238 | 88 |
The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Response is defined as a reduction (from baseline to endpoint) of 50% or more in the MADRS total score.
| percentage of participants | Olanzapine (Open-label Treatment Period) |
|---|---|
| Percentage of Participants With Symptomatic Response in Montgomery-Asberg Depression Rating (MADRS) Depression Rating (Open-Label Phase) | 43.7 |
Percentage of participants with symptomatic remission at any time as defined as a score of less than or equal to 12 in the MADRS total score. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
| percentage of participants | Olanzapine (Open-label Treatment Period) |
|---|---|
| Percentage of Participants With Symptomatic Remission in the MADRS Total Score (Open-Label Phase) | 85.1 |
Percentage of participants with recovery defined as a value of less than or equal to 12 in the MADRS total score for at least 4 weeks of post-baseline treatment. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).
| percentage of participants | Olanzapine (Open-label Treatment Period) |
|---|---|
| Percentage of Participants With Recovery (Open-Label Phase) | 69.9 |
The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.
| units on a scale | Olanzapine (Open-label Treatment Period) |
|---|---|
| Baseline | 1.11 ± 2.87 |
| Change | -0.03 ± 2.55 |
Emergence of mania is defined as first occurrence of score of \>=15 in the YMRS total score in the Open-Label Extension. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.
| percentage of participants | Olanzapine (Open-label Treatment Period) |
|---|---|
| Percentage of Participants With Emergence of Mania During the Study (Open-Label Phase) | 0.8 |
EPS symptoms measured by DIEPSS are grouped into 4 categories: parkinsonism, akathisia, dystonia, and dyskinesia. Severity is assessed at 5 levels, from level 0 (none, normal) to level 4 (severe). For Parkinsonism, normal baseline is defined as a score not \>=3 on 1 item nor \>=2 on 2 items; abnormal endpoint is defined as a score \>=3 on 1 item or \>=2 on 2 items, or an increase of 3 on Parkinsonism total. Baseline akathisia, dystonia and dyskinesia is defined as a score \<2; abnormal endpoint is a score \>=2 or an increase \>= 2 from that baseline score.
| percentage of participants | Olanzapine (Open-label Treatment Period) |
|---|---|
| Akathisia (N=378) | 0.8 |
| Dyskinesia (N=385) | 0.3 |
| Dystonia (N=385) | 0.0 |
| Parkinsonism (N=385) | 1.0 |
| millimeters of mercury | Olanzapine (Open-label Treatment Period) |
|---|---|
| Baseline-Standing Diastolic (N=361) | 74.98 ± 10.77 |
| Change- Standing Diastolic (N=361) | 0.15 ± 8.28 |
| Baseline- Sitting Diastolic (N=383) | 73.32 ± 10.73 |
| Change- Sitting Diastolic (N=383) | -0.03 ± 8.68 |
| Baseline- Standing Systolic (N=361) | 112.06 ± 14.58 |
| Change- Standing Systolic (N=361) | 0.96 ± 10.37 |
| Baseline- Sitting Systolic (N=383) | 112.26 ± 14.45 |
| Change- Sitting Systolic (N=383) | 0.27 ± 10.28 |
| Baseline- Orthostatic Change-Diastolic (N=358) | 1.75 ± 5.25 |
| Change- Orthostatic Change- Diastolic (N=358) | 0.16 ± 6.56 |
| Baseline- Orthostatic Change- Systolic (N=358) | 0.19 ± 6.19 |
| Change- Orthostatic Change- Systolic (N=358) | 0.65 ± 7.92 |
| kilograms | Olanzapine (Open-label Treatment Period) |
|---|---|
| Baseline | 68.31 ± 18.54 |
| Change | 2.27 ± 4.00 |
| gram/Liter | Olanzapine (Open-label Treatment Period) |
|---|---|
| Baseline- Albumin | 42.64 ± 3.58 |
| Change- Albumin | 0.53 ± 2.86 |
| Baseline- Total Protein | 73.24 ± 4.39 |
| Change- Total Protein | 0.56 ± 3.78 |
| units/Liter | Olanzapine (Open-label Treatment Period) |
|---|---|
| Baseline- Alkaline Phosphatase | 68.58 ± 19.33 |
| Change- Alkaline Phosphatase | 2.37 ± 12.85 |
| Baseline- CPK | 107.36 ± 133.21 |
| Change- CPK | -1.73 ± 124.56 |
| Baseline- GGT | 28.90 ± 32.08 |
| Change- GGT | 0.78 ± 25.90 |
| millimole/Liter | Olanzapine (Open-label Treatment Period) |
|---|---|
| Baseline | 103.62 ± 2.16 |
| Change | 0.33 ± 2.38 |
| micromole/Liter | Olanzapine (Open-label Treatment Period) |
|---|---|
| Baseline | 67.48 ± 14.98 |
| Change | 2.05 ± 7.90 |
| trillion cells per liter (Tril/L) | Olanzapine (Open-label Treatment Period) |
|---|---|
| Baseline | 4.64 ± 0.53 |
| Change | 0.03 ± 0.30 |
| millimole/Liter of iron (Fe) | Olanzapine (Open-label Treatment Period) |
|---|---|
| Baseline | 8.61 ± 1.01 |
| Change | 0.04 ± 0.51 |
| billion cells per liter (BILL/L) | Olanzapine (Open-label Treatment Period) |
|---|---|
| Baseline | 257.96 ± 64.25 |
| Change | -4.56 ± 49.94 |
| microgram/Liter | Olanzapine (Open-label Treatment Period) |
|---|---|
| Baseline | 21.64 ± 18.48 |
| Change | -3.41 ± 17.20 |
| micromole/Liter | Olanzapine (Open-label Treatment Period) |
|---|---|
| Baseline | 324.74 ± 89.39 |
| Change | 14.73 ± 56.80 |
| millimole/Liter | Olanzapine (Open-label Treatment Period) |
|---|---|
| Baseline- Fasting Glucose (N=375) | 5.20 ± 0.57 |
| Change- Fasting Glucose (N=375) | 0.06 ± 0.63 |
| Baseline- Cholesterol (N=380) | 4.96 ± 1.08 |
| Change- Cholesterol (N=380) | 0.05 ± 0.70 |
| Baseline- Triglycerides (N=380) | 1.55 ± 1.06 |
| Change- Triglycerides (N=380) | 0.10 ± 0.97 |
| Baseline- LDL Cholesterol (N=378) | 2.88 ± 0.91 |
| Change- LDL Cholesterol (N=378) | 0.06 ± 0.63 |
| Baseline- HDL Cholesterol (N=380) | 1.39 ± 0.40 |
| Change- HDL Cholesterol (N=380) | -0.05 ± 0.24 |
Time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole, fixed correction factor (QTcF interval); Bazett-Corrected QT Interval (QTcB interval).
| milliseconds | Olanzapine (Open-label Treatment Period) |
|---|---|
| Baseline- QTcF | 410.09 ± 19.44 |
| Change- QTcF | 1.80 ± 15.07 |
| Baseline- QTcB | 421.72 ± 19.61 |
| Change- QTcB | 1.76 ± 16.69 |
| beats per minute | Olanzapine (Open-label Treatment Period) |
|---|---|
| Baseline | 71.85 ± 11.64 |
| Change | 0.06 ± 10.79 |
The MINI module C (MINI-C) is a rating scale for severity of suicidal thoughts and behaviors. The MINI-C is composed of 12 Yes/No questions with variable scores assigned to each question. The scale ranges from 0 to 52 with higher scores indicating a greater presence of suicidal thoughts and/or behaviors. Based upon scores, suicidality is defined as Low (1-8), Medium (9-16), and High (\>=17).
| percentage of participants | Olanzapine (Open-label Treatment Period) |
|---|---|
| Percentage of Participants With High Suicidality at Endpoint (Open-Label Phase) | 1.3 |
Please refer to the Adverse Event overview for details regarding adverse events and serious adverse events.
| participants | Olanzapine (Open-label Treatment Period) |
|---|---|
| Serious | 14 |
| Non-Serious | 209 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Olanzapine | — | 6/343 (1.7%) | 238/343 (69.4%) |
| Placebo | — | 7/171 (4.1%) | 88/171 (51.5%) |
| Olanzapine (Open Label Treatment Period | — | 14/389 (3.6%) | 209/389 (53.7%) |
| Event | Olanzapine | Placebo | Olanzapine (Open Label Treatment Period |
|---|---|---|---|
| Bipolar I disorderPsychiatric disorders | 1/343 | 2/171 | 1/389 |
| Suicidal ideationPsychiatric disorders | 1/343 | 2/171 | 1/389 |
| Drug exposure during pregnancyInjury, poisoning and procedural complications | 0/343 | 1/171 | 0/389 |
| AnxietyPsychiatric disorders | 0/343 | 1/171 | 0/389 |
| DepressionPsychiatric disorders | 0/343 | 1/171 | 1/389 |
| Depressive symptomPsychiatric disorders | 0/343 | 1/171 | 0/389 |
| InsomniaPsychiatric disorders | 0/343 | 1/171 | 0/389 |
| Completed suicidePsychiatric disorders | 0/343 | 0/171 | 2/389 |
| Suicide attemptPsychiatric disorders | 0/343 | 0/171 | 2/389 |
| PancreatitisGastrointestinal disorders | 1/343 | 0/171 | 1/389 |
| Event | Olanzapine | Placebo | Olanzapine (Open Label Treatment Period |
|---|---|---|---|
| Weight increasedInvestigations | 59/343 | 6/171 | 67/389 |
| SomnolenceNervous system disorders | 59/343 | 11/171 | 17/389 |
| Increased appetiteMetabolism and nutrition disorders | 46/343 | 4/171 | 15/389 |
| SedationNervous system disorders | 29/343 | 4/171 | 3/389 |
| NasopharyngitisInfections and infestations | 24/343 | 6/171 | 20/389 |
| ConstipationGastrointestinal disorders | 19/343 | 5/171 | 6/389 |
| Dry mouthGastrointestinal disorders | 18/343 | 6/171 | 4/389 |
| NauseaGastrointestinal disorders | 7/343 | 8/171 | 4/389 |
| HeadacheNervous system disorders | 15/343 | 8/171 | 10/389 |
| InsomniaPsychiatric disorders | 11/343 | 8/171 | 8/389 |
| Age Continuous(years) | Olanzapine | Placebo | Total |
|---|---|---|---|
| Mean | 35.93 ± 11.13 | 34.96 ± 11.02 | 35.61 ± 11.09 |
| Sex: Female, Male(Participants) | Olanzapine | Placebo | Total |
|---|---|---|---|
| Female | 205 | 95 | 300 |
| Male | 138 | 76 | 214 |
| Race/Ethnicity, Customized(participants) | Olanzapine | Placebo | Total |
|---|---|---|---|
| Caucasian | 36 | 22 | 58 |
| African | 18 | 4 | 22 |
| Hispanic | 6 | 3 | 9 |
| East Asian | 282 | 141 | 423 |
| Native American | 1 | 1 | 2 |
| Region of Enrollment(participants) | Olanzapine | Placebo | Total |
|---|---|---|---|
| China | 140 | 70 | 210 |
| Japan | 104 | 52 | 156 |
| Korea, Republic of | 20 | 10 | 30 |
| Taiwan | 19 | 9 | 28 |
| United States | 60 | 30 | 90 |
| Age at onset, Bipolar I Disorder(years) | Olanzapine | Placebo | Total |
|---|---|---|---|
| Mean | 27.57 ± 10.98 | 26.12 ± 9.90 | 27.09 ± 10.64 |
The record gives a start of Aug 2007, a primary completion of Mar 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olanzapine